Listen
ADCETRIS (brentuximab vedotin)
Reason for request
Key points
Unfavourable opinion for reimbursement in the first-line treatment of adult patients with CD30+ Stage IV Hodgkin lymphoma (HL).
Role in the care pathway?
The first-line treatment of adults with Hodgkin lymphoma is based on chemotherapy, following by radiotherapy in the event of persistent disease. The chemotherapy protocols used are ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) protocols.
The choice of protocol depends primarily on the clinical stage of the disease, the presence of certain risk factors and the patient’s characteristics (age, medical history, general health, etc.).
Role of the medicinal product in the care pathway
ADCETRIS in combination with AVD chemotherapy has no role in the treatment of previously untreated adult patients with CD30+ Stage IV Hodgkin lymphoma (HL).
Clinical Benefit
| Insufficient |
The clinical benefit of ADCETRIS is insufficient in view of the available alternatives to justify its funding by the French national health insurance system in the treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD). |
